A study to evaluate the use of a fixed-dose combination of pertuzumab and trastuzumab given as an injection under the skin for treating people with HER2-positive early breast cancer
-
Cancer -
Breast Cancer -
HER2-positive Early Breast Cancer
For the latest version of this information please go to www.forpatients.roche.com